Welcome to our dedicated page for Longeveron news (Ticker: LGVNR), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron LLC is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. Their lead investigational product candidate, LMSC, is based on a specialized cell known as a mesenchymal stem cell derived from the bone marrow of healthy young adult donors. The company's allogeneic, 'off-the-shelf' product is under investigation for chronic conditions of the elderly and other life-threatening diseases with no approved therapeutics currently available, including aging frailty syndrome, Alzheimer's disease, hypoplastic left heart syndrome, and the metabolic syndrome.
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announced the exercise of warrants for $6.2 million gross proceeds. The company entered into agreements for the exercise of 2,399,744 shares of its Class A common stock at an exercise price of $2.35 per share. H.C. Wainwright & Co. is the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.79%
Tags
-
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announces that its CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B™ in mild Alzheimer’s Disease has been accepted for a Featured Research Oral Presentation at the 2024 Alzheimer’s Association International Conference. The company will also present a poster at the conference. CEO Wa’el Hashad expresses excitement for sharing the study results at the leading forum for Alzheimer’s disease clinical investigation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
73.37%
Tags
-
Rhea-AI Summary
Longeveron Inc. (LGVN) closes public offering, raising $5.2 million for clinical and regulatory development of Lomecel-B™. Board members and insiders participate in the offering. The Company also amends existing warrants to lower exercise price and extend expiration dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.34%
Tags
Rhea-AI Summary
Longeveron Inc. announces a public offering of 2,234,043 shares of Class A common stock and warrants at $2.35 per share, aiming to raise capital for the development of cellular therapies for various conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
-
Rhea-AI Summary
Longeveron Inc. (LGVN) CEO updates shareholders on strategic roadmap and key priorities for 2024, focusing on regenerative medicine development. The company's lead product, Lomecel-B™, shows promise in treating Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer’s Disease, with positive trial results and FDA designations. Longeveron aims for HLHS commercialization, strategic collaborations, efficient resource management, and financial stewardship.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
-
Rhea-AI Summary
Longeveron Inc. (LGVN) announces a 1-for-10 reverse stock split to increase per-share trading price and regain Nasdaq compliance. The split will convert every ten shares into one, reducing outstanding shares significantly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.13%
Tags
Rhea-AI Summary
Longeveron Inc. announces 2024 strategic priorities focusing on advancing Lomecel-B™ in HLHS and Alzheimer’s disease. The company presented long-term survival data from ELPIS I trial at the American Heart Association, with additional clinical data from CLEAR MIND Phase 2a trial in Alzheimer’s disease. Financially, revenues decreased by 42% in 2023, with a gross profit decrease of 56%. General and administrative expenses increased by 40%, while research and development expenses decreased by 3%. Net loss increased by 14% in 2023. The company discontinued its Aging-related Frailty clinical trial in Japan to focus on HLHS and Alzheimer’s disease programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.04%
Tags
-
Rhea-AI Summary
Longeveron Inc. (LGVN) will report its 2023 financial results on February 27, 2024, followed by a conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
-
Rhea-AI Summary
Longeveron Inc. announces receipt of a notice of patent allowance from the United States Patent and Trademark Office for Medicinal Signaling Cells (MSCs), the technology behind its lead investigational product Lomecel-BTM. The new patent impacts patients with Aging-related Frailty receiving vaccines for conditions such as Covid and the flu, adding to the company's growing patent estate. Longeveron is conducting a trial of Aging-related Frailty in Japan and recently announced positive results from its Phase 2 Alzheimer’s disease trial. The patent covers the impact of Lomecel-BTM on favorable modulation of the immune system, which is foundational in all of Longeveron’s indications under development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announced the closing of a registered direct offering, raising approximately $2.36 million for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.96%
Tags
FAQ
What is Longeveron LLC known for?
Longeveron LLC is known for developing innovative cellular therapeutics for chronic life-threatening diseases.
What is LMSC?
LMSC is Longeveron's lead investigational product candidate based on a specialized mesenchymal stem cell derived from healthy young adult donors.
What kind of diseases does Longeveron focus on?
Longeveron focuses on chronic conditions of the elderly and other life-threatening diseases such as aging frailty syndrome, Alzheimer's disease, hypoplastic left heart syndrome, and the metabolic syndrome.
What is the unique selling point of Longeveron's products?
Longeveron's products are allogeneic, 'off-the-shelf' solutions for diseases where no approved therapeutics currently exist.
Who are the investors of Longeveron Inc.?
Investors can contact Derek Cole at Investor Relations Advisory Solutions for more information.
How can one get in touch with Longeveron LLC?
For inquiries, contact Derek Cole at Investor Relations Advisory Solutions.
What are the latest developments at Longeveron Inc.?
Stay updated with the latest news and events related to Longeveron Inc. by contacting Derek Cole at Investor Relations Advisory Solutions.
Where can I find more information about Longeveron Inc.?
For more information, visit Longeveron Inc.'s official website or contact Derek Cole at Investor Relations Advisory Solutions.
What are the current projects of Longeveron LLC?
Longeveron LLC is actively working on developing cellular therapeutics for chronic life-threatening diseases, including aging frailty syndrome, Alzheimer's disease, hypoplastic left heart syndrome, and the metabolic syndrome.
How does Longeveron's approach differ from traditional therapeutics?
Longeveron's approach involves utilizing mesenchymal stem cells from healthy young adult donors as an allogeneic, 'off-the-shelf' solution for chronic conditions with no approved therapeutics.
Longeveron Inc.